SRNE Sorrento Therapeutics Inc

Price (delayed)

$2.06

Market cap

$801.23M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.56

Enterprise value

$938.21M

Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases. Sorrento's multimodal, multipronged approach to fighting cancer is made ...

Highlights
The revenue has increased by 23% YoY and by 8% from the previous quarter
The company's gross profit rose by 17% YoY and by 4.4% QoQ
SRNE's equity has soared by 188% QoQ but it is down by 2.1% YoY
SRNE's quick ratio is down by 45% year-on-year but it is up by 39% since the previous quarter
The company's net income has shrunk by 104% YoY and by 10% QoQ
The EPS has shrunk by 68% YoY and by 8% QoQ

Key stats

What are the main financial stats of SRNE
Market
Shares outstanding
388.95M
Market cap
$801.23M
Enterprise value
$938.21M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.11
Price to sales (P/S)
12.18
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
16.45
Earnings
Revenue
$57.03M
EBIT
-$492.39M
EBITDA
-$475.47M
Free cash flow
-$326.59M
Per share
EPS
-$1.56
Free cash flow per share
-$0.97
Book value per share
$0.66
Revenue per share
$0.17
TBVPS
$1.53
Balance sheet
Total assets
$855.64M
Total liabilities
$629.44M
Debt
$248.88M
Equity
$226.54M
Working capital
$126.89M
Liquidity
Debt to equity
1.1
Current ratio
1.62
Quick ratio
1.45
Net debt/EBITDA
-0.29
Margins
EBITDA margin
-833.7%
Gross margin
73%
Net margin
-827%
Operating margin
-746.1%
Efficiency
Return on assets
-61.2%
Return on equity
-302.8%
Return on invested capital
-127.5%
Return on capital employed
-75.6%
Return on sales
-863.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SRNE stock price

How has the Sorrento Therapeutics stock price performed over time
Intraday
-9.65%
1 week
22.62%
1 month
42.07%
1 year
-79.4%
YTD
-55.7%
QTD
-11.59%

Financial performance

How have Sorrento Therapeutics's revenue and profit performed over time
Revenue
$57.03M
Gross profit
$41.63M
Operating income
-$425.53M
Net income
-$471.65M
Gross margin
73%
Net margin
-827%
The company's net income has shrunk by 104% YoY and by 10% QoQ
Sorrento Therapeutics's net margin has shrunk by 67% YoY and by 2.1% QoQ
Sorrento Therapeutics's operating income has decreased by 49% YoY and by 6% QoQ
The revenue has increased by 23% YoY and by 8% from the previous quarter

Growth

What is Sorrento Therapeutics's growth rate over time

Valuation

What is Sorrento Therapeutics stock price valuation
P/E
N/A
P/B
3.11
P/S
12.18
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
16.45
The EPS has shrunk by 68% YoY and by 8% QoQ
SRNE's equity has soared by 188% QoQ but it is down by 2.1% YoY
SRNE's price to book (P/B) is 74% less than its last 4 quarters average of 13.5 and 49% less than its 5-year quarterly average of 6.7
SRNE's price to sales (P/S) is 61% lower than its last 4 quarters average of 34.8 and 41% lower than its 5-year quarterly average of 22.9
The revenue has increased by 23% YoY and by 8% from the previous quarter

Efficiency

How efficient is Sorrento Therapeutics business performance
The return on invested capital has dropped by 185% year-on-year and by 14% since the previous quarter
The ROE has shrunk by 143% YoY and by 11% QoQ
The ROS has shrunk by 85% YoY
The return on assets has dropped by 51% year-on-year

Dividends

What is SRNE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SRNE.

Financial health

How did Sorrento Therapeutics financials performed over time
Sorrento Therapeutics's total assets is 36% higher than its total liabilities
The total liabilities has surged by 64% year-on-year and by 2.1% since the previous quarter
SRNE's quick ratio is down by 45% year-on-year but it is up by 39% since the previous quarter
Sorrento Therapeutics's debt is 10% higher than its equity
SRNE's equity has soared by 188% QoQ but it is down by 2.1% YoY
Sorrento Therapeutics's debt to equity has surged by 64% YoY but it has shrunk by 64% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.